PMS-Pazopanib 200 mg tablet; Presence of Sorafenib
Last updated
Summary
Product
PMS-Pazopanib 200 mg tablet
Issue
Health products - Product quality
What to do
Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns.
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot number |
|---|---|---|---|---|---|
Pharmascience |
PMS-Pazopanib 200 mg tablet |
DIN 02525666 |
Tablet |
Pazopanib hydrochloride 200 mg |
E0201K, E0201J |
Issue
Presence of Sorafenib in affected lots.
What you should do
- Verify if your product is affected.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Pharmascience Inc.
6111 Avenue Royalmount,
Montréal, Québec, H4P 2T4, Canada
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type II
Identification number
RA-73740
Get notified
Receive notifications for new and updated recalls and alerts by category.